MX337511B - Medicamentos y metodos para tratar cefaleas. - Google Patents

Medicamentos y metodos para tratar cefaleas.

Info

Publication number
MX337511B
MX337511B MX2012011936A MX2012011936A MX337511B MX 337511 B MX337511 B MX 337511B MX 2012011936 A MX2012011936 A MX 2012011936A MX 2012011936 A MX2012011936 A MX 2012011936A MX 337511 B MX337511 B MX 337511B
Authority
MX
Mexico
Prior art keywords
botulinum toxin
headache
medicaments
methods
patient
Prior art date
Application number
MX2012011936A
Other languages
English (en)
Inventor
Mitchell F Brin
Catherine C Turkel
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/789,180 external-priority patent/US9078892B2/en
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX337511B publication Critical patent/MX337511B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un trastorno de uso excesivo de medicación para el dolor agudo (tal como un trastorno de cefalea por uso excesivo de medicación) se puede tratar por administración de una toxina botulínica a un paciente. Una cefalea puede ser tratada más eficazmente por administración conjunta de una toxina botulínica y un medicamento de triptano a un paciente y/o se puede incrementar la eficacia de una medicación de triptano. La toxina botulínica puede ser toxina botulínica tipo A y la toxina botulínica se puede administrar a, o en la vecindad del lugar en donde el paciente experimenta o está predispuesto a experimentar dolor o una cefalea.
MX2012011936A 2004-02-26 2006-08-22 Medicamentos y metodos para tratar cefaleas. MX337511B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/789,180 US9078892B2 (en) 2004-02-26 2004-02-26 Methods for treating pain and for treating a medication overuse disorder
US11/039,506 US20050191321A1 (en) 2004-02-26 2005-01-18 Methods for treating headache

Publications (1)

Publication Number Publication Date
MX337511B true MX337511B (es) 2016-03-09

Family

ID=34914767

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012011936A MX337511B (es) 2004-02-26 2006-08-22 Medicamentos y metodos para tratar cefaleas.

Country Status (17)

Country Link
US (10) US20050191321A1 (es)
EP (3) EP2752197B1 (es)
JP (1) JP4913721B2 (es)
KR (1) KR20060126793A (es)
CN (1) CN103251937B (es)
AU (2) AU2005216887A1 (es)
BR (1) BRPI0508231A (es)
CA (2) CA2982313A1 (es)
CY (1) CY1115104T1 (es)
DK (1) DK1725253T3 (es)
ES (1) ES2460731T3 (es)
HK (2) HK1098072A1 (es)
MX (1) MX337511B (es)
PL (1) PL1725253T3 (es)
PT (1) PT1725253E (es)
SI (1) SI1725253T1 (es)
WO (1) WO2005082339A2 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US9078892B2 (en) * 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US20050191321A1 (en) * 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US7922983B2 (en) * 2005-07-28 2011-04-12 Kimberly-Clark Worldwide, Inc. Sterilization wrap with additional strength sheet
US7223234B2 (en) 2004-07-10 2007-05-29 Monitrix, Inc. Apparatus for determining association variables
WO2006078588A2 (en) * 2005-01-18 2006-07-27 Allergan, Inc. Improved methods for treating headache
US7749515B2 (en) 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
AU2012241076B2 (en) * 2005-02-01 2015-05-14 Allergan, Inc. Targeted delivery of Botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
US7655244B2 (en) 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
FR2889936B1 (fr) 2005-09-01 2007-12-21 Sod Conseils Rech Applic Methode pour quantifier une neurotoxine cholinergique dans un echantillon
US7824694B2 (en) * 2006-01-12 2010-11-02 Allergan, Inc. Methods for enhancing therapeutic effects of a neurotoxin
FR2902341B1 (fr) 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
US9061025B2 (en) * 2006-08-31 2015-06-23 Allergan, Inc. Methods for selecting headache patients responsive to botulinum toxin therapy
US20080103546A1 (en) * 2006-10-27 2008-05-01 Cyberonics, Inc. Patient management system for treating epilepsy using an implantable medical device
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
US8617571B2 (en) * 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
US8940308B2 (en) 2010-03-30 2015-01-27 Allergan, Inc. Methods for treating depression
US9144600B2 (en) 2011-07-14 2015-09-29 Allergan, Inc. Methods for treatment of incontinence associated with sexual activity
US20130236446A1 (en) 2012-03-12 2013-09-12 William J. Binder Treatment of migraine headache with diffusion of toxin in non-muscle related areas of the mouth
ES2759478T3 (es) 2012-03-12 2020-05-11 William J Binder Tratamiento de las cefaleas por migraña con neurotoxina presináptica
ES2424294B1 (es) 2012-03-22 2014-07-21 Lipotec, S.A. Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
BR112014025396B1 (pt) 2012-04-13 2020-03-17 Lubrizol Advanced Materials, Inc. Composto, composição cosmética ou farmacêutica, e, uso de um composto
EP2919807B1 (en) 2012-11-16 2018-07-11 Finzi, Eric Treatment of post-traumatic stress disorder using botulinum toxin a
EP2976060B1 (en) 2013-03-22 2016-10-26 Lipotec, S.A. Exopolysaccharide for the treatment and/or care of the skin, mucous membranes and/or nails
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
WO2015073441A1 (en) * 2013-11-12 2015-05-21 Finzi Eric Treatment of social anxiety disorder, obsessive compulsive disorder and panic disorder using botulinum toxin
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
WO2016149092A1 (en) 2015-03-13 2016-09-22 Allergan, Inc. Improved injection paradigm for administration of botulinum toxins
EP3436054B2 (en) 2016-09-13 2022-07-27 Allergan, Inc. Stabilized non-protein clostridial toxin compositions
US10932711B2 (en) 2017-02-27 2021-03-02 Payman Sadeghi Method and system for neurohydrodissection
US10456419B2 (en) 2017-02-27 2019-10-29 Payman Sadeghi Method for treating migraine headaches
CA3057304A1 (en) * 2017-03-22 2018-09-27 Bonti, Inc. Botulinum neurotoxins for treating traumatic injuries
WO2019005773A1 (en) * 2017-06-26 2019-01-03 Bonti, Inc. CLOSTRIDIAL NEUROTOXIN FORMULATIONS AND USE
WO2021188844A2 (en) * 2020-03-18 2021-09-23 Revance Therapeutics, Inc. Injectable botulinum toxin methods for treating headaches

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
EP1477183B1 (en) * 1993-12-28 2005-11-02 Allergan, Inc. Neurotoxic component of Botulinum toxin for modulating cholinergic controlled secretions
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US5670484A (en) 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
EP0758900B1 (en) 1994-05-09 2002-04-10 BINDER, William J. Botulinum toxin FOR REDUCTION OF migraine HEADACHE PAIN
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US5670181A (en) * 1995-10-20 1997-09-23 Stokes; Christine P. Apparatus and method for slip casting for ceramic objects
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
BR9914891A (pt) * 1998-10-27 2001-07-17 Mayo Foundation Processos para aperfeiçoamento de cura de ferimento
US6358917B1 (en) * 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth
US6139845A (en) * 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
DE60125986T3 (de) * 2000-02-08 2011-07-28 Allergan, Inc., 92612, Calif. Pharmazeutische Zusammensetzungen mit Botulinum Toxin
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) * 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US6787517B1 (en) * 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
ES2312651T3 (es) 2001-07-27 2009-03-01 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Toxina botulinum en el tratamiento o prevencion del acne.
US6623742B2 (en) * 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
DE10150415A1 (de) 2001-10-11 2003-05-15 Andres O Ceballos-Baumann Arzneimittel zur Prophylaxe und Therapie von Depressionen
EP1487481A4 (en) * 2002-03-01 2005-11-23 Elan Pharm Inc METHOD FOR TREATING NERVE TERMINATION SYNDROMES
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
EP1599221B1 (en) * 2003-03-06 2011-12-28 Botulinum Toxin Research Associates, Inc. Treatment of sinusitis related chronic facial pain and headache with botulinum toxin
US7393537B2 (en) * 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
US6838434B2 (en) * 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US8734810B2 (en) * 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8609112B2 (en) * 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8609113B2 (en) * 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8048423B2 (en) 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
US7270287B2 (en) 2004-01-06 2007-09-18 Allergan, Inc. Botulinum toxin treatment for kinesia
US20050191321A1 (en) * 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US9078892B2 (en) * 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US8603779B2 (en) * 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8512984B2 (en) * 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US7655244B2 (en) 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
US7749515B2 (en) * 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
TWI282083B (en) * 2005-05-27 2007-06-01 Innolux Display Corp Backlight on/off control circuit
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US20090317377A1 (en) * 2005-08-26 2009-12-24 Yeomans David C Therapy procedure for drug delivery for trigeminal pain
US7824694B2 (en) * 2006-01-12 2010-11-02 Allergan, Inc. Methods for enhancing therapeutic effects of a neurotoxin
US20080021437A1 (en) * 2006-04-27 2008-01-24 Boyd James P Enhancement of the efficacy of a clenching reduction device by augmenting with botulinum toxin type A
GB0610867D0 (en) * 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
US9061025B2 (en) * 2006-08-31 2015-06-23 Allergan, Inc. Methods for selecting headache patients responsive to botulinum toxin therapy
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
US8617571B2 (en) * 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
CA2823974A1 (en) * 2010-01-08 2011-07-14 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of migraine headaches
US8940308B2 (en) * 2010-03-30 2015-01-27 Allergan, Inc. Methods for treating depression
US9144600B2 (en) * 2011-07-14 2015-09-29 Allergan, Inc. Methods for treatment of incontinence associated with sexual activity
US20130236446A1 (en) * 2012-03-12 2013-09-12 William J. Binder Treatment of migraine headache with diffusion of toxin in non-muscle related areas of the mouth
JP6377052B2 (ja) * 2012-04-03 2018-08-22 ビーエイエスエフ・ソシエタス・エウロパエアＢａｓｆ Ｓｅ 植物レシチンを含む毛髪化粧料組成物
US9005628B2 (en) * 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
CN104981690B (zh) * 2013-02-06 2018-02-02 安捷伦科技有限公司 流体连接装置、组件及相关方法
US20140294923A1 (en) * 2013-02-20 2014-10-02 Questcor Pharmaceuticals, Inc. Acth for treatment of migraine headache
WO2014150899A1 (en) * 2013-03-15 2014-09-25 Chapin Matthew J Topical ophthalmic formulations for treating migraine
EP3137053B1 (en) * 2014-04-30 2020-06-17 Allergan, Inc. Formulations of biologics for intravesical instillation
CA2960960A1 (en) * 2014-09-12 2016-03-17 Allergan, Inc. Methods for treating osteoarthritis pain
WO2016149092A1 (en) * 2015-03-13 2016-09-22 Allergan, Inc. Improved injection paradigm for administration of botulinum toxins

Also Published As

Publication number Publication date
DK1725253T3 (da) 2014-07-07
US20100189655A1 (en) 2010-07-29
CA2557588C (en) 2017-11-28
PT1725253E (pt) 2014-05-06
EP1725253A2 (en) 2006-11-29
HK1098072A1 (en) 2007-07-13
US10092631B2 (en) 2018-10-09
US7704511B2 (en) 2010-04-27
US9078893B2 (en) 2015-07-14
EP2752197B1 (en) 2019-11-20
JP4913721B2 (ja) 2012-04-11
US20190038726A1 (en) 2019-02-07
CY1115104T1 (el) 2016-12-14
WO2005082339A2 (en) 2005-09-09
US20090263426A1 (en) 2009-10-22
HK1199403A1 (en) 2015-07-03
US20060104995A1 (en) 2006-05-18
CN103251937A (zh) 2013-08-21
US20200230217A1 (en) 2020-07-23
US8889151B2 (en) 2014-11-18
US20220088157A1 (en) 2022-03-24
AU2011201107A1 (en) 2011-04-07
CA2557588A1 (en) 2005-09-09
US20050191321A1 (en) 2005-09-01
BRPI0508231A (pt) 2007-07-17
WO2005082339A3 (en) 2005-12-01
AU2011201107B2 (en) 2012-12-20
US20060121057A1 (en) 2006-06-08
SI1725253T1 (sl) 2014-05-30
KR20060126793A (ko) 2006-12-08
CN103251937B (zh) 2015-10-07
EP2433643B1 (en) 2015-12-02
US9555085B2 (en) 2017-01-31
US10603366B2 (en) 2020-03-31
EP2433643A1 (en) 2012-03-28
ES2460731T3 (es) 2014-05-14
US20170128552A1 (en) 2017-05-11
PL1725253T3 (pl) 2014-08-29
US20150313974A1 (en) 2015-11-05
AU2005216887A1 (en) 2005-09-09
CA2982313A1 (en) 2005-09-09
EP1725253B1 (en) 2014-04-09
JP2007525505A (ja) 2007-09-06
EP2752197A1 (en) 2014-07-09

Similar Documents

Publication Publication Date Title
MX337511B (es) Medicamentos y metodos para tratar cefaleas.
IL171607A (en) Use of botulinum toxin for the treatment of sinusitis-induced headaches
NZ588648A (en) Suture line administration technique using botulinum toxins
WO2007100675A3 (en) Collagenase for treating cellulite
WO2009086072A3 (en) Therapy of rituximab-refractory rheumatoid arthritis patients
DE60023476D1 (de) Kombination von doctaxel und rhumab her2 zür krebsbehandlung
ATE452652T1 (de) Behandlung neurologischer und neuropsychiatrischer erkrankungen mit botulinumtoxin
MX2007008764A (es) Metodos para tratar capsulitis adhesiva.
CA2549550A1 (en) Botulinum toxin therapy for skin disorders
CY1107484T1 (el) Παραγωγα γκελνταναμυκινης χρησιμοποιουμενα για τη θεραπεια καρκινου
WO2008039898A3 (en) Methods for the treatment of a traumatic central nervous system injury
MX2010012860A (es) Metodos para tratar cancer del sistema nervioso central.
HK1086186A1 (en) Use of spongosine (2-methoxyadenosein) for preparing pharmaceutical for the treatment of pain
IS8187A (is) Meðferð á fráhvarfseinkennum
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
MX2022005303A (es) Agentes y usos de los mismos para prevenir y/o tratar enfermedades neurologicas.
FR2910327B1 (fr) Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
WO2007100590A3 (en) Methods for treating cellulite
WO2006078588A3 (en) Improved methods for treating headache
EA200600284A1 (ru) Дооперационное лечение послеоперационной боли
GB0405381D0 (en) A method and means for treating heart failure
ATE545423T1 (de) Mittel zur behandlung von lungenkrebs
RU2006119263A (ru) Способ лечения больных розацеа
WO2008060535A3 (en) Use of reversine and analogs for treatment of cancer
WO2005102367A3 (en) Coadministration of radiation, efaproxiral sodium, and supplemental oxygen for the treatment of cancer